is Íslenska en English

Lokaverkefni (Meistara)

Háskóli Íslands > Verkfræði- og náttúruvísindasvið > Meistaraprófsritgerðir - Verkfræði- og náttúruvísindasvið >

Vinsamlegast notið þetta auðkenni þegar þið vitnið til verksins eða tengið í það:

  • Titill er á ensku Adaptive Laboratory Evolution of Escherichia coli MG1655 WT and tolC Knock-out towards Bile Acid and Antibiotic Resistance
  • Meistara
  • Útdráttur er á ensku

    The human microbiome is composed of various commensal and pathogenic microorganisms. Collective research efforts and recent technology have revealed enormous information and contributed to the knowledge of the field so far. Studies have described the structure and functional capabilities of the human microbiome in the healthy state and in a variety of disease states. Multi-drug resistance (MDR) poses one of the greatest threats to human health worldwide as bacterial pathogens evolved to withstand antimicrobials and ever-changing environmental conditions more than ever. As the research regarding drug resistance reveals more information over the past decades, one of the most prominent intrinsic self-defense mechanisms, membrane bound tripartite bacterial multi-drug efflux protein acrAB-tolC which removes a wide range of drugs and toxic compounds taken up by bacteria is found to be greatly associated with MDR in gut microbiome. The overexpression of these efflux system causes MDR and resistance optimization is driven by mutations in regulatory genes such as marR and acrR which known to increase the expression level of the many other resistance factors including acrAB-tolC protein itself. In this master thesis, the role of tolC efflux channel and in what extend it contributes to MDR in commensal gut bacteria Escherichia coli is assessed in multiple drug evolution settings with chloramphenicol, tetracycline, bile acid mixture and deoxycholic acid using de novo adaptive laboratory evolution method. The findings showed that the absence of fully intact acrAB-tolC and especially tolC channel has a substantial decrease in drug resistance and could not be compensated with any of the most common resistance regulation factors.

  • Styrktaraðili er á ensku Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark (DTU)
  • 3.2.2020

Skráarnafn Stærð AðgangurLýsingSkráartegund 
Adaptive Laboratory Evolution of Escherichia coli MG1655 WT and tolC Knock-out towards Bile Acid and Antibiotic Resistance.pdf1.64 MBLokaður til...31.01.2022HeildartextiPDF
Supplementary File 1.pdf101.18 kBLokaður til...31.01.2022FylgiskjölPDF
Supplementary File 2.pdf103.97 kBLokaður til...31.01.2022FylgiskjölPDF
Supplementary File 3.pdf101.01 kBLokaður til...31.01.2022FylgiskjölPDF
Declaration of Access.pdf175.29 kBLokaðurYfirlýsingPDF